The estimated Net Worth of Kevin Norrett is at least $5.47 Milion dollars as of 11 September 2023. Mr. Norrett owns over 9,000 units of Sierra Oncology Inc stock worth over $5,394,629 and over the last 4 years he sold SRRA stock worth over $77,191. In addition, he makes $0 as Chief Business Officer at Sierra Oncology Inc.
Kevin has made over 2 trades of the Sierra Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of SRRA stock worth $15,480 on 11 September 2023.
The largest trade he's ever made was selling 16,854 units of Sierra Oncology Inc stock on 8 February 2023 worth over $77,191. On average, Kevin trades about 2,350 units every 20 days since 2020. As of 11 September 2023 he still owns at least 98,102 units of Sierra Oncology Inc stock.
You can see the complete history of Mr. Norrett stock trades at the bottom of the page.
Kevin Norrett serves as Chief Business Officer of the Company. Mr. Kevin Norrett brings more than 20 years of experience to Sierra and over the course of his career has become an expert at helping clinical stage companies transition to full commercialization. Most recently, Kevin was Chief Commercial Officer at Angion Biomedica, a clinical stage company with a focus in acute organ injury and fibrosis. Prior to Angion, he served as Vice President of Marketing, Market Access & Commercial Operations at Aimmune Therapeutics, where he helped build the commercial department and launch strategy for the first product approved to treat peanut allergy. Prior to joining Aimmune, Kevin was Vice President, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching Lokelma®, the company's first therapeutic to treat hyperkalemia. Before ZS Pharma, he held commercial leadership roles at Exelixis and Genentech, where he launched multiple new products and line extensions in oncology and hematology. Kevin's career also includes several years of corporate finance and manufacturing experience with SG Cowen's Health Care Investment Banking Group and with SyStemix, a stem-cell therapy company acquired by Novartis. Mr. Norrett earned an M.B.A. from the Haas School of Business at the University of California, Berkeley , an M.S. in Biochemistry and Molecular Biology from University of California, Los Angeles and a B.S. in Biological Sciences from the University of California , Davis.
Kevin's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth oraz James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: